Table 1.
Baseline and treatment characteristics of patients
| Patient ID | Sex | Age | ECOG | Disease pathology | BCL6/BCL2/C-Myc expression | Prior lines of therapy and most recent response | Prior lines of therapy | Site of diseases | Ann Arbor staging | IPI scores | LDH (U/L) | β2 microglobulin (mg/L) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 50 | 3 | DLBCL, non-GCB | No | Radiotherapy, PD | 8 | Primary CNS lymphomas (right posterior margin of corpus callosum) | IEa | 2 | 363 | 6.10 |
| R + HD-MTX + TMZ, PR and then PD | ||||||||||||
| Ibutinib, PD | ||||||||||||
| Thalidomide, SD | ||||||||||||
| PD-1 inhibitor + pemetrexed, PD | ||||||||||||
| PD-1 inhibitor* + pemetrexed + carboplatin, PD | ||||||||||||
| Daunorubicin + lenalidomide + tcmozolomidc, PD | ||||||||||||
| Etoposide + ifosfamide, SD | ||||||||||||
| 2 | F | 55 | 2 | DLBCL, ABC, NOS | BCL6/BCL2/C-Myc | R-CDOP, PR | 5 | Mainly in the thoracic cavity, the abdominal cavity, the pelvic cavity and the right thigh | IVa | 3 | 400 | 3.00 |
| R-EPCOH, SD | ||||||||||||
| R-ICE + lenalidomide, PR and then PD | ||||||||||||
| ICE, PR and then PD | ||||||||||||
| R-ICE, PR and then PD | ||||||||||||
| 3 | F | 54 | 1 | DLBCL, GCB | No | Mastectomy | 4 | Mainly in the right eyeball, and the pelvic cavity | IVb | 3 | 317 | 4.00 |
| R-CODOX, CR and then relapse | ||||||||||||
| Radiotherapy, PD | ||||||||||||
| PD-1 inhibitor* + GVD, relapse | ||||||||||||
| 4 | M | 40 | 1 | DLBCL, GCB | BCL6/BCL2 | R-CHOP, CR and then relapse | 4 | In the area II of right neck, and the pelvic cavity | IVa | 2 | 183 | 2.70 |
| PD-1 inhibitor + GVD, PR and then SD | ||||||||||||
| PD-1 inhibitor + ICE, PD | ||||||||||||
| PD-1 inhibitor* + paclitaxel, PD | ||||||||||||
| 5 | M | 71 | 1 | DLBCL, ABC, NOS | BCL6/C-Myc | R-CHOP,CR | 4 | In the hepatogastric space-pancreatic head | IIEa | 2 | 200 | 4.80 |
| R + CVD, NA | ||||||||||||
| R maintenance, relapse | ||||||||||||
| Gemox, PD | ||||||||||||
| R maintenance, PD | ||||||||||||
| 6 | F | 33 | 1 | DLBCL, GCB, NOS | BCL6/BCL2/C-Myc | R-CHO.NA | 6 | Mainly in the abdominal cavity | IVa | 2 | 128 | 4.80 |
| R-CNO,NA | ||||||||||||
| R-GDP,PD | ||||||||||||
| R2-GDP, NA | ||||||||||||
| R2-GDP + etoposide, PR | ||||||||||||
| R-CHOP, PD | ||||||||||||
| 7 | F | 42 | 2 | DLBCL, ABC, NOS | BCL6/BCL2/C-Myc | R-CHOP, PR and then PD | 2 | Mainly in the thoracic cavity and the abdominal cavity | IVa | 3 | 1197 | 1.50 |
| R2-ICE, PR and then PD | ||||||||||||
| 8 | M | 52 | 1 | DLBCL, GCB, NOS | BCL67BCL2/C-Myc | R-CHOP, PD | 3 | In the left heart diaphragm and retroperitoneal space | IIIEb | 2 | 224 | 3.10 |
| R + DA-EPOCH, PD | ||||||||||||
| R-GDP, PD |
*The duration between last PD-1 inhibitor and date of infusion was 161 days for patient 12, 14 days for patient 3, and 41 days for patient 4. DLBCL: diffuse large B-cell lymphoma; GCB: germinal center B-cell; ABC: activated B-cell; NOS: not otherwise specified; PD: progressive disease; PR: partial response; SD: stable disease; CR: complete response; NA: not available; R: rituximab; HD-MTX: high-dose methotrexate; TMZ: temozolomide; CDOP: cyclophosphamide, liposomal doxorubicin, vincristine, prednisone; EPCOH: etoposide, doxorubicin, vincristine, cyclophosphamide, prednisone; ICE:ifosfamide, carboplatin, etoposide; CODOX: cyclophosphamide, adriamycin, vincristine, intrathecal injection of methotrexate, cytarabine; GVD: gemcitabine, doxorubicin liposome, vinorelbine; CHOP: cyclophosphamide, adriamycin, vincristine, prednisone; CVD: cyclophosphamide, vinoresin, dexamethasone; Gemox: gemcitabine, oxaliplatin; CHO: cyclophosphamide, epirubicin, vinoresin; CNO: cyclophosphamide, mitoxantrone, vinoresin; GDP:Gemcitabine, cisplatin, dexamethasone; R2: rituximab, lenalidomide; DA: dose-adjusted; LDH: lactate dehydrogenase. LDH normally ranges from 109 to 245 U/L and β2 microglobulin from 1.0 to 3.0 mg/L